IDEAYA Biosciences (IDYA) vs Organon (OGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
IDEAYA Biosciences (IDYA) has outperformed Organon (OGN) over the past year, gaining 34.7% versus a gain of 30.1%. Over five years, IDYA leads with a +56.8% price change compared with -60.5% for OGN. Organon is the larger company by market cap ($3.62 billion vs $3.41 billion), about 1.1 times the size, while IDEAYA Biosciences is growing revenue faster (+3024.4% vs -2.9%).
Organon pays a dividend yielding 0.58%, while IDEAYA Biosciences does not currently pay one. Organon converts more of its revenue into profit, with a net margin of 3.0% versus -52.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDYA | OGN |
|---|---|---|
| Share price | $35.37 | $13.79 |
| Market cap | $3.41B | $3.62B |
| 1-day change | -2.45% | 0.00% |
| YTD return | +4.89% | +92.33% |
| 1-year return | +34.70% | +30.09% |
| 5-year return | +56.77% | -60.48% |
| P/E ratio (TTM) | — | 17.68 |
| Forward P/E | — | 3.81 |
| EPS (TTM) | $-1.94 | $0.78 |
| Dividend yield | 0.00% | 0.58% |
| Annual dividend | $0.00 | $0.08 |
| Revenue (latest FY) | $218.71M | $6.22B |
| Revenue growth (YoY) | +3024.43% | -2.92% |
| Net income (latest FY) | $-113.70M | $187.00M |
| Gross margin | — | 53.30% |
| Operating margin | -72.84% | — |
| Net margin | -51.99% | 3.01% |
| 52-week high | $42.68 | $13.79 |
| 52-week low | $26.05 | $5.69 |
| Distance from 52-week high | -17.13% | 0.00% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +49.14% | -18.42% |
| Average volume | 785.95K | 2.64M |
| Shares outstanding | 96.49M | 262.61M |
| Employees | 145 | 10,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Organon is more profitable, keeping 3.0 cents of every revenue dollar as net income versus -52.0 cents for IDEAYA Biosciences.
- IDEAYA Biosciences grew revenue faster in its latest fiscal year (+3024.43% vs -2.92%).
About IDEAYA Biosciences
IDYA stock →IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
About Organon
OGN stock →Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 10,000 employees
IDYA vs OGN FAQ
Which is bigger, IDEAYA Biosciences or Organon?
Organon (OGN) is larger, with a market capitalization of $3.62B compared with $3.41B for IDEAYA Biosciences (IDYA).
Which stock has performed better over the past year, IDYA or OGN?
IDYA returned +34.70% over the past 12 months, compared with +30.09% for OGN (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, IDEAYA Biosciences or Organon?
Organon pays a dividend yielding 0.58%, while IDEAYA Biosciences does not currently pay a regular dividend.
Are IDEAYA Biosciences and Organon in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.